Jubilant Pharmova Limited has informed the Exchange that Record date for the purpose of DI is 24-Jul-2026.
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Pharmova reported strong FY2026 results with consolidated revenue growing 14.5% to Rs 83,456 million from Rs 72,913 million. Profit after tax surged 37% to Rs 5,464 million from Rs 3,985 million, driven by robust performance across segments. Consolidated EBITDA margin stood at approximately 11.8% (before interest and tax). The board recommended a final dividend of Rs 5 per share (500%). Exceptional items of Rs 1,064 million net (including Rs 535 million remediation costs, Rs 236 million asset sale gain, Rs 133 million labour code impact, Rs 96 million debt costs, Rs 64 million associate impairment) were noted. Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion. Operating cash flow was healthy at Rs 12,268 million. Record date for dividend payment is July 24, 2026.
Strong earnings growth with 37% PAT increase signals solid operational performance. The clean auditor opinion removes concerns. Dividend payout of Rs 5 per share provides direct shareholder value. The remediation costs at Montreal facility represent a one-time drag but are manageable given cash generation.